These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 24392350)
1. Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approaches. Daniotti JL; Vilcaes AA; Torres Demichelis V; Ruggiero FM; Rodriguez-Walker M Front Oncol; 2013 Dec; 3():306. PubMed ID: 24392350 [TBL] [Abstract][Full Text] [Related]
2. Dysregulated Expression of Glycolipids in Tumor Cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents. Daniotti JL; Lardone RD; Vilcaes AA Front Oncol; 2015; 5():300. PubMed ID: 26779443 [TBL] [Abstract][Full Text] [Related]
3. Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy. Durrant LG; Noble P; Spendlove I Clin Exp Immunol; 2012 Feb; 167(2):206-15. PubMed ID: 22235996 [TBL] [Abstract][Full Text] [Related]
4. Harnessing potential role of gangliosides in immunomodulation and cancer therapeutics. Hegde M; Girisa S; Aswani BS; Alqahtani MS; Abbas M; Sethi G; Kunnumakkara AB Life Sci; 2024 Aug; 351():122786. PubMed ID: 38848944 [TBL] [Abstract][Full Text] [Related]
5. Glycosylation of glycolipids in the Golgi complex. Maccioni HJ J Neurochem; 2007 Nov; 103 Suppl 1():81-90. PubMed ID: 17986143 [TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of immunotoxin by antibody to ganglioside GD3: a novel drug delivery route for tumor cells. Torres Demichelis V; Vilcaes AA; Iglesias-Bartolomé R; Ruggiero FM; Daniotti JL PLoS One; 2013; 8(1):e55304. PubMed ID: 23383146 [TBL] [Abstract][Full Text] [Related]
7. Cancer vaccines: an update with special focus on ganglioside antigens. Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591 [TBL] [Abstract][Full Text] [Related]
8. Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Hakomori S Cancer Res; 1985 Jun; 45(6):2405-14. PubMed ID: 3886132 [No Abstract] [Full Text] [Related]
9. [Gangliosides as carbohydrate antigens associated with cancer and their possible use in tumor immunotherapy]. Horwacik I Przegl Lek; 2004; 61 Suppl 2():14-9. PubMed ID: 15686040 [TBL] [Abstract][Full Text] [Related]
10. Glycolipid antigens of human polymorphonuclear neutrophils and the inducible HL-60 myeloid leukemia line. Symington FW; Hedges DL; Hakomori S J Immunol; 1985 Apr; 134(4):2498-506. PubMed ID: 3855933 [TBL] [Abstract][Full Text] [Related]
11. Glycolipids of murine lymphocyte subpopulations: a defect in the levels of sialidase-sensitive sialosylated asialo GM1 in beige mouse lymphocytes. Schwarting GA; Gajewski A J Immunol; 1981 Jun; 126(6):2403-7. PubMed ID: 6971898 [TBL] [Abstract][Full Text] [Related]
12. Biosynthetic Machinery Involved in Aberrant Glycosylation: Promising Targets for Developing of Drugs Against Cancer. Vasconcelos-Dos-Santos A; Oliveira IA; Lucena MC; Mantuano NR; Whelan SA; Dias WB; Todeschini AR Front Oncol; 2015; 5():138. PubMed ID: 26161361 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of glycosylation by amphomycin and sugar nucleotide analogs PP36 and PP55 indicates that Haloferax volcanii beta-glucosylates both glycoproteins and glycolipids through lipid-linked sugar intermediates: evidence for three novel glycoproteins and a novel sulfated dihexosyl-archaeol glycolipid. Zhu BC; Drake RR; Schweingruber H; Laine RA Arch Biochem Biophys; 1995 Jun; 319(2):355-64. PubMed ID: 7786016 [TBL] [Abstract][Full Text] [Related]
14. Glycans as targets for therapeutic antitumor antibodies. Rabu C; McIntosh R; Jurasova Z; Durrant L Future Oncol; 2012 Aug; 8(8):943-60. PubMed ID: 22894669 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12. Bozeman EN; He S; Shafizadeh Y; Selvaraj P Hum Vaccin Immunother; 2016; 12(2):421-30. PubMed ID: 26308597 [TBL] [Abstract][Full Text] [Related]
16. Expression and localization of Lewis(x) glycolipids and GD1a ganglioside in human glioma cells. Ariga T; Bhat S; Kanda T; Yamawaki M; Tai T; Kushi Y; Kasama T; Handa S; Yu RK Glycoconj J; 1996 Apr; 13(2):135-45. PubMed ID: 8737237 [TBL] [Abstract][Full Text] [Related]
17. Cell surface glycoconjugates as possible target structures for human natural killer cells: evidence against the involvement of glycolipids and N-linked carbohydrate chains. Voshol H; Dullens HF; Den Otter W; Vliegenthart JF Glycobiology; 1993 Feb; 3(1):69-76. PubMed ID: 8448387 [TBL] [Abstract][Full Text] [Related]
18. Targeting Fleurence J; Fougeray S; Bahri M; Cochonneau D; Clémenceau B; Paris F; Heczey A; Birklé S J Immunol Res; 2017; 2017():5604891. PubMed ID: 28154831 [TBL] [Abstract][Full Text] [Related]
19. Fucosylation of glycolipids in PC12 cells is dependent on the sequence of nerve growth factor treatment and adenylate cyclase activation. Schwarting GA; Tischler AS; Donahue SR Dev Neurosci; 1990; 12(3):159-71. PubMed ID: 2364894 [TBL] [Abstract][Full Text] [Related]
20. Lipid changes in Niemann-Pick disease type C brain: personal experience and review of the literature. Vanier MT Neurochem Res; 1999 Apr; 24(4):481-9. PubMed ID: 10227680 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]